The National Institutes of Health (NIH) has awarded a $2-million grant to support research into the role of infections…
Vanda Pinto, PhD
​​Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Vanda Pinto, PhD
Alzamend Neuro has requested approval from the U.S. Food and Drug Administration (FDA) to begin clinical trials to test…
The University of Wisconsin School of Medicine and Public Health is recruiting participants for a Phase 3 trial that…
The U.S. Food and Drug Administration has named Eli Lilly’s donanemab a breakthrough therapy for treating Alzheimer’s disease, the…